IDEXX Laboratories Investor Presentation — November 2022

Document content

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3RevenueOperating

Reported growth: of Revenue

Organic growth: YoY change in basis points:

CAG Diagnostics Recurring

Organic growth: Reported

Comparable Comparable growth:

Q3 Premium Instrument

PlacementsWW U.S. Intl

Catalyst 2,191 694 1,497

New and competitive 1,518 337 1,181

Hematology1,994 589 1,405

SediVue® Dx 552 351 201

TOTAL 4,737 1,634 3,103

SediVue Installed Base

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3

2022 2020 2021CAG Water LPD

Revenue $765M Revenue $41M Revenue $28M

Reported growth: +4% Reported growth: +7% Reported growth: (2%)

Organic growth: +8% Organic growth: +12% Organic growth: +7%

For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX’s 2022 third quarter earnings

release issued on November 1, 2022 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.IDEXX Q3 2022 Earnings Highlights (NASDAQ: IDXX)

year over yearOrganic

CAG Diagnostics Recurring $667M +5% +9%

IDEXX VetLab® Consumables $263M +4% +9%

Rapid Assay Products $81M +5% +7%

Reference Laboratory Dx and

Consulting Services$296M +5% +8%

CAG Diagnostics Services and

Accessories$28M +8% +13%

Preview truncated — download the full document for the complete content.